1. Cost-effectiveness of antenatal anti-D prophylaxis.
- Author
-
Vick S, Cairns J, Urbaniak S, Whitfield C, and Raafat A
- Subjects
- Cohort Studies, Cost-Benefit Analysis methods, Cost-Benefit Analysis statistics & numerical data, Dose-Response Relationship, Drug, Erythroblastosis, Fetal prevention & control, Female, Forecasting, Health Services Research economics, Health Services Research methods, Humans, Infant, Newborn, Models, Economic, Parity immunology, Pregnancy, Prenatal Care methods, Quality-Adjusted Life Years, Retrospective Studies, Rho(D) Immune Globulin administration & dosage, Scotland, State Medicine economics, Value of Life, Erythroblastosis, Fetal economics, Health Care Costs statistics & numerical data, Prenatal Care economics, Rho(D) Immune Globulin economics
- Abstract
This paper estimates the incremental cost-effectiveness of providing antenatal anti-D prophylaxis in varying dose sizes to either primigravidae or all Rh D negative women. It presents a model for calculating the net cost per 1000 'at risk' women based on the costs of anti-D prophylaxis and the future NHS costs avoided. Incremental cost-effectiveness is measured in terms of the net cost per Rh D-alloimmunization and the net cost per Rh HD loss prevented. Programmes for Rh D negative primigravidae are more cost-effective than the same dose protocol extended to all Rh D negative women. The 1 x 1250 iu programme is the most cost-effective option.
- Published
- 1996
- Full Text
- View/download PDF